BS

Inotiv IncDUS Inotiv Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.04

Micro

Exchange

XDUS - Boerse Duesseldorf

BS50.DU Stock Analysis

BS

Uncovered

Inotiv Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-43/100

Low score

Market cap $B

0.04

Dividend yield

Shares outstanding

25.607 B

Inotiv, Inc. is an international contract research company that is providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Its DSA segment supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Its RMS segment offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

View Section: Eyestock Rating